Related Experiment Videos
Nonhuman primate models for evaluation of AIDS therapy
H M McClure1, D C Anderson, A A Ansari
1Yerkes Regional Primate Research Center, School of Medicine, Emory University, Atlanta, Georgia 30322.
Annals of the New York Academy of Sciences
|January 1, 1990
Summary
Simian immunodeficiency virus (SIV) in macaques models human AIDS, aiding antiretroviral drug and vaccine research. Early AZT treatment showed protection against a lethal SIV variant, but other drugs were ineffective in chronic models.
Area of Science:
- Veterinary Medicine
- Virology
- Immunology
Background:
- Simian immunodeficiency virus (SIV) infection in macaque monkeys serves as a crucial animal model for human immunodeficiency virus (HIV) research.
- SIV shares genetic, antigenic, and biologic similarities with HIV, making macaques valuable for studying AIDS pathogenesis and therapeutic interventions.
Purpose of the Study:
- To evaluate the efficacy of antiretroviral drugs as prophylactic treatments in SIV-infected macaque models.
- To assess the potential of SIV-infected macaques in modeling HIV-like disease and testing novel vaccines.
Main Methods:
- Infection of macaque monkeys with simian immunodeficiency virus (SIV).
- Administration of antiretroviral drugs, including AZT, CS-87, D4T, and FDT, for prophylactic treatment trials.
- Observation of disease progression, clinical signs, hematologic abnormalities, and survival rates in infected macaques.
Main Results:
- SIV infection in macaques recapitulates key features of human AIDS, including immunosuppression and opportunistic infections.
- Preliminary trials indicated that AZT provided some protection when administered within 24 hours of exposure to an acutely lethal SIV variant.
- Other antiretroviral drugs (CS-87, AZT, D4T, FDT) showed no prophylactic efficacy in the chronic SIV infection model.
Conclusions:
- The macaque model is highly relevant for studying HIV pathogenesis and evaluating antiretroviral therapies.
- Early intervention with AZT may offer prophylactic benefits against acute SIV infection, warranting further investigation.
- Current antiretroviral drugs lack prophylactic efficacy in established chronic SIV infection models, highlighting the need for more effective therapeutic strategies.